| The Senate Committee has backed drug exclusivity for
biologics for 12 years. There was a strong movement to limit the time
period to a much shorter time frame, but the bill is moving forward with a
recommendation for 12 years. There still remains opposition from the
Administration, FDA and other legislators for 5-7 years, however, so the
final passage of the 12 year protection remains uncertain.
http://online.wsj.com/article/BT-CO-20090713-715216.html?mod=dist_smartbrief
|
